1. Home
  2. ONMD vs CING Comparison

ONMD vs CING Comparison

Compare ONMD & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneMedNet Corp

ONMD

OneMedNet Corp

HOLD

Current Price

$0.73

Market Cap

56.0M

Sector

N/A

ML Signal

HOLD

CING

Cingulate Inc.

BUY

Current Price

$4.90

Market Cap

59.3M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
ONMD
CING
Founded
2006
2012
Country
United States
United States
Employees
23
14
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.0M
59.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ONMD
CING
Price
$0.73
$4.90
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$34.50
AVG Volume (30 Days)
225.3K
760.5K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$3.16
52 Week High
$4.22
$11.89

Technical Indicators

Market Signals
Indicator
ONMD
CING
Relative Strength Index (RSI) 37.15 50.67
Support Level $0.60 $4.69
Resistance Level $0.96 $5.35
Average True Range (ATR) 0.07 0.60
MACD -0.01 0.07
Stochastic Oscillator 8.30 82.66

Price Performance

Historical Comparison
ONMD
CING

About ONMD OneMedNet Corp

OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: